Magnetic resonance imaging (MRI) frequently underestimates tumor size in patients with prostate cancer, according to a study published in the Journal of Urology.1,2
In the study, the underestimation of tumor size by MRI occurred most frequently when measuring smaller tumors and those with a low PI-RADS, a score used to measure the likelihood that a suspicious area is a cancer.
MRI is a key tool in the prostate cancer armamentarium. With this study, the investigators, led by researchers at theUCLA Jonsson Comprehensive Cancer Center, drew specific attention to the impact of their findings on prostate ablation therapy.
Ablation techniques, such as cryotherapy, HIFU, and laser ablation, are highly dependent on the accuracy of tumor size estimates. Thus, underestimation of tumor size creates the high potential for undertreatment.
Multiparametric magnetic resonance imaging frequently underestimates pathological tumor size and the degree of underestimation increases with smaller radiologic tumor size and lower PI-RADSv2 scores. Therefore, a larger ablation margin may be required for smaller tumors and lesions with lower PI-RADSv2 scores. These variables must be considered when estimating treatment margins in focal therapy, the authors wrote in their conclusion.
The analysis included 461 lesions in 441 patients with concordant 3T mpMRI and pathological region of interest. The median ...